Trastuzumab: hopes and realities

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Breast cancer treatment faces challenges with refractory and resistant disease, necessitating novel therapies.
• Existing treatments require improvement in effectiveness, tolerability, and tumor specificity.

Purpose of the Study:

• To evaluate the efficacy and tolerability of Trastuzumab (Herceptin) as a targeted therapy for HER2-positive breast cancer.
• To assess Trastuzumab's role in various treatment settings, including first-line, second-line, and third-line therapy, alone and in combination with chemotherapy.

Main Methods:

• Clinical trials involving patients with HER2-positive breast cancer.
• Administration of Trastuzumab as a single agent and in combination with chemotherapy (e.g., paclitaxel).
• Assessment of treatment outcomes including tumor response, time to disease progression, duration of response, time to treatment failure, and overall survival.

Main Results:

• Trastuzumab demonstrated durable tumor responses as a second- or third-line monotherapy.
• First-line combination therapy with Trastuzumab and paclitaxel significantly improved progression-free survival and overall survival (25% increase vs. chemotherapy alone).
• Patients with HER2 gene amplification or high HER2 overexpression (3+) experienced the greatest clinical benefit.

Conclusions:

• Trastuzumab is the first monoclonal antibody and gene-product-targeted therapy to show significant survival benefits in breast cancer.
• Trastuzumab offers improved efficacy, tolerability, and tumor specificity, representing a breakthrough in breast cancer management.
• The development of Trastuzumab serves as a model for integrating future gene-targeted therapies to enhance patient survival and quality of life.